<DOC>
	<DOCNO>NCT03021915</DOCNO>
	<brief_summary>This single center , prospective , control pilot safety research study . The primary objective research study ass safety use OvaPrime procedure woman diagnose either primary ovarian insufficiency ( POI ) poor ovarian response ( POR ) . A maximum seventy ( 70 ) subject enrol achieve target sample size 60 Modified Intent-to-Treat ( mITT ) subject primary analysis population . Each subject shall one ovary expose EggPC cell contralateral ovary expose EggPC vehicle mean subject serve control . Results treatment control ovary examine relevant endpoint antral follicle count . The duration research study estimate approximately 6 year total , period span enrollment ( estimate approximately six month ) , eight month last hyperstimulation completion 5-year follow-up ( main study protocol one year primary endpoint LTFU sub-study extend 5 additional year ) .</brief_summary>
	<brief_title>Single Center , Prospective Controlled Pilot Study OvaPrime Procedure</brief_title>
	<detailed_description />
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<criteria>1 . Subjects diagnose EITHER POI POR define : POI subject : &lt; 40 year age nondetectable AMH FSH &gt; 15.0 mIU/ml and/or symptom menopause Duration POI &lt; 24 month Duration POI ≥ 2 year &lt; 5 year ( n=10 ) Duration POI ≥ 5 year &lt; 10 year ( n=10 ) POR ( base European Society Human Reproduction Embryology ( ESHRE ) guideline must two follow : 40 year age A previous IVF cycle &lt; 3 oocyte standard care control ovarian hyperstimulation protocol An abnormal ovarian reserve test define : 1 . AFC &lt; 5 7 follicle 2 . AMH &lt; 0.5 1.1 ng/ml 3 . Highest ever baseline FSH &gt; 15.0 ml U/ml 2 . Subject must ovary . 3 . Subject agree participate main study follow well Long Term Followup ( LTFU ) substudy 4 . Subject 's male partner sperm donor source must meet following requirement : Semen must ejaculate ( surgically derive , epididymal , testicular , electro ejaculated sperm ) , collect ejaculation . Male partner 's testis must expose chemotherapy . Semen must morphologically normal spermatozoon accord World Health Organization ( see table ) adequate concentration motile spermatozoa insemination oocytes intracytoplasmic sperm injection ( ICSI ) . WHO Semen variable 2010 Volume ( mL ) 1.5 Concentration ( 106 mL−1 ) 15 Total sperm number ( 106/ejaculate ) 39 Motility ( % motile ) 40 ( + b + c ) Forward progression 32 ( + b ) Morphology ( % normal ) 4 Viability/vitality ( % live ) 58 White blood cell ( 106 mL−1 ) &lt; 1.0 5 . Partner must also agree research study requirement include follow ( include main study well LTFU substudy ) offspring sign consent form ( applicable case woman use sperm donation ) . 1 . Subject diagnosis POI ≥ 40 year age &lt; 21 year age time OvaPrime procedure 2 . Subject diagnosis POR &gt; 45 year age time OvaPrime procedure 3 . Subject prior surgery/medical condition would prevent direct access ovary ( e.g. , pelvic adhesion , tubo ovarian adhesion location/displacement ovary ( y ) high body mass index ( BMI ) ) . 4 . Subject severe ( stage IV ) endometriosis presence endometrioma 5 . Subject unilateral bilateral untreated hydrosalpinx 6 . Subject participate active phase another investigational trial within previous 30 day 7 . Subject history prior chemotherapy radiation therapy pelvis 8 . Subjects and/or partner ( supply sperm ) know karyotypic abnormality 9 . Subjects FMR1 premutations FMRI mutation 10 . Subjects positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>